In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

Gatto F, Feelders RA, Franck SE, van Koetsveld PM, Dogan F, Kros JM, Neggers SJCMM, van der Lely AJ, Lamberts SWJ, Ferone D, Hofland LJ

The Journal of clinical endocrinology and metabolism1 Jun 2017Cited by 51 (Europe PMC)

PMID28323931DOI10.1210/jc.2017-00135PepBankPUB-28323931

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Efficacy outcome
In primary GH-oma cultures, pasireotide reduced GH secretion by 37.1%.
In plain wordsIn cells from GH-secreting pituitary tumors, pasireotide reduced growth hormone secretion by 37.1%.
Peptide
Pasireotide
Outcome
DecreaseGH secretion reduction
Study
humann: not reported in source
Primary GH-secreting pituitary adenoma cultures
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 nM · 72 hoursAs given in this study (human).
Measurements
GH secretion change
−37.1%
pasireotide
Source sentences
Summary
The overall effect of OCT (-36.8%) and PAS (-37.1%) on GH secretion was superimposable.
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)-secreting pituitary adenomas (GH-omas).
Summary · context
The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures.
Summary · context
OCT and PAS treatment for 72 hours (10 nM).
Report a problemFND-2832393101
02LabIn vitro (cells)Efficacy outcome
In primary GH-oma cultures, pasireotide and octreotide had superimposable overall effects on GH secretion.
In plain wordsIn cells from GH-secreting pituitary tumors, pasireotide and octreotide reduced growth hormone secretion similarly.
Peptide
Pasireotide
Outcome
No significant changeGH secretion versus octreotide
Study
humann: not reported in source
Primary GH-secreting pituitary adenoma cultures
Comparator
Octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 nM · 72 hoursAs given in this study (human).
Source sentences
Summary
The overall effect of OCT (-36.8%) and PAS (-37.1%) on GH secretion was superimposable.
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)-secreting pituitary adenomas (GH-omas).
Summary · context
The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures.
Summary · context
OCT and PAS treatment for 72 hours (10 nM).
Report a problemFND-2832393102
03LabIn vitro (cells)Efficacy outcome
In GH-oma cultures, pasireotide was more effective in six, equally effective in 22, and less effective in five compared with octreotide.
In plain wordsIn tumor cells, pasireotide was more effective than octreotide in six cultures, equally effective in 22, and less effective in five.
Peptide
Pasireotide
Outcome
MixedRelative GH response subgroups
Study
humann: not reported in source
Primary GH-secreting pituitary adenoma cultures
Comparator
Octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 nM · 72 hoursAs given in this study (human).
Measurements
PAS more effective
6 cultures
PAS more effective than OCT
Equal response
22 cultures
PAS equals OCT
OCT more effective
5 cultures
OCT more effective than PAS
Source sentences
Summary
We identified three adenoma groups: PAS+ (PAS more effective than OCT), n = 6; PAS = OCT, n = 22; and OCT+ (OCT more effective than PAS), n = 5.
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)-secreting pituitary adenomas (GH-omas).
Summary · context
The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures.
Summary · context
OCT and PAS treatment for 72 hours (10 nM).
Report a problemFND-2832393103
04LabIn vitro (cells)Efficacy outcome
In primary GH-oma cultures, pasireotide inhibited PRL hypersecretion more than octreotide (P < 0.01).
In plain wordsIn tumor cells, pasireotide reduced excess prolactin secretion more than octreotide.
Peptide
Pasireotide
Outcome
DecreasePRL hypersecretion
Study
humann: not reported in source
Primary GH-secreting pituitary adenoma cultures
Comparator
Octreotide
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 nM · 72 hoursAs given in this study (human).
Source sentences
Summary
PAS inhibited PRL hypersecretion more than OCT (P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)-secreting pituitary adenomas (GH-omas).
Summary · context
The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures.
Summary · context
OCT and PAS treatment for 72 hours (10 nM).
Report a problemFND-2832393106

Studies that did not test the peptide alone2

In this study, Pasireotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pasireotide.

05LabNot a test of Pasireotide aloneIn vitro (cells)Mechanism
In GH-oma cultures, the subgroup responding better to pasireotide than octreotide had lower sst2 mRNA than other response groups (P < 0.05).
In plain wordsIn tumor cells, better response to pasireotide than octreotide was associated with lower sst2 messenger RNA than in other response groups.
Peptide
Pasireotide
Outcome
Decreasesst2 mRNA in response subgroups
Study
humann: not reported in source
Primary GH-secreting pituitary adenoma cultures
Comparator
Other adenoma response groups
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
PAS+ adenomas showed lower somatostatin receptor subtype (sst)2 messenger RNA (mRNA) and sst2/sst5 mRNA ratio, compared with the other groups (P < 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
We identified three adenoma groups: PAS+ (PAS more effective than OCT), n = 6; PAS = OCT, n = 22; and OCT+ (OCT more effective than PAS), n = 5.
Summary · context
To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)-secreting pituitary adenomas (GH-omas).
Summary · context
The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures.
Summary · context
OCT and PAS treatment for 72 hours (10 nM).
In this study, Pasireotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pasireotide.
Report a problemFND-2832393104
06LabNot a test of Pasireotide aloneIn vitro (cells)Mechanism
In GH-oma cultures, the subgroup responding better to pasireotide than octreotide had a lower sst2/sst5 mRNA ratio than other groups (P < 0.05).
In plain wordsIn tumor cells, better response to pasireotide than octreotide was associated with a lower receptor messenger RNA ratio than other response groups.
Peptide
Pasireotide
Outcome
Decreasesst2/sst5 mRNA ratio in response subgroups
Study
humann: not reported in source
Primary GH-secreting pituitary adenoma cultures
Comparator
Other adenoma response groups
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
PAS+ adenomas showed lower somatostatin receptor subtype (sst)2 messenger RNA (mRNA) and sst2/sst5 mRNA ratio, compared with the other groups (P < 0.05).
4 context sentences(design, population, supporting numbers)
Summary · context
We identified three adenoma groups: PAS+ (PAS more effective than OCT), n = 6; PAS = OCT, n = 22; and OCT+ (OCT more effective than PAS), n = 5.
Summary · context
To compare the antisecretory effect of OCT and PAS in primary cultures of growth hormone (GH)-secreting pituitary adenomas (GH-omas).
Summary · context
The effect of OCT and PAS on GH (and PRL) secretion was tested in 33 GH-oma cultures.
Summary · context
OCT and PAS treatment for 72 hours (10 nM).
In this study, Pasireotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pasireotide.
Report a problemFND-2832393105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.